3,680 Shares in Insulet Corporation $PODD Acquired by Ausdal Financial Partners Inc.

Ausdal Financial Partners Inc. purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,680 shares of the medical instruments supplier’s stock, valued at approximately $1,136,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PODD. NewEdge Advisors LLC grew its position in shares of Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 64 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its position in Insulet by 4.3% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 10,587 shares of the medical instruments supplier’s stock valued at $3,326,000 after purchasing an additional 441 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Insulet by 7.6% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,260 shares of the medical instruments supplier’s stock valued at $5,423,000 after purchasing an additional 1,219 shares during the last quarter. Meridian Wealth Management LLC boosted its stake in Insulet by 15.0% during the 2nd quarter. Meridian Wealth Management LLC now owns 1,362 shares of the medical instruments supplier’s stock worth $428,000 after purchasing an additional 178 shares during the period. Finally, Creative Planning grew its position in Insulet by 1.6% during the 2nd quarter. Creative Planning now owns 8,408 shares of the medical instruments supplier’s stock worth $2,642,000 after purchasing an additional 136 shares during the last quarter.

Insulet Stock Up 2.2%

Shares of Insulet stock opened at $224.66 on Tuesday. The company has a market cap of $15.82 billion, a P/E ratio of 64.19, a PEG ratio of 1.31 and a beta of 1.42. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. Insulet Corporation has a one year low of $216.49 and a one year high of $354.88. The firm has a fifty day moving average of $257.29 and a two-hundred day moving average of $296.01.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. During the same quarter last year, the business earned $1.15 EPS. The business’s revenue was up 31.2% on a year-over-year basis. On average, analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

PODD has been the topic of a number of recent research reports. Royal Bank Of Canada lifted their price objective on shares of Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Oppenheimer decreased their target price on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. Evercore set a $340.00 price target on Insulet in a research report on Thursday, February 19th. JPMorgan Chase & Co. reduced their price objective on Insulet from $415.00 to $340.00 and set an “overweight” rating for the company in a research note on Thursday, February 19th. Finally, Canaccord Genuity Group decreased their price objective on Insulet from $450.00 to $435.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Twenty equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $354.24.

Insider Buying and Selling

In other news, Director Michael R. Minogue acquired 2,030 shares of Insulet stock in a transaction that occurred on Wednesday, February 25th. The stock was purchased at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.39% of the stock is currently owned by insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.